Skip to main content
. 2014 Jul 24;2(6):953–959. doi: 10.3892/mco.2014.359

Figure 3.

Figure 3

Survival of epithelial growth factor receptor (EGFR) wild-type patients. (A) Patients with a progression-free survival after initial pemetrexed-based chemotherapy (PFS1) of ≥10 months exhibited a longer PFS after the rechallenge (PFS2) compared to those with a PFS1 of <10 months. (B) Patients with a PFS1 of ≥10 months had a longer overall survival (OS) compared to those with a PFS1 of <10 months. (C) Patients with a treatment-free survival (TFS) of ≥3 months exhibited a longer PFS2 compared to those with a TFS of <3 months. (D) Patients with a TFS of ≥3 months tended to have a longer OS compared to those with a TFS of <3 months.